Novartis India Limited (NOVARTIND.BO)
INR 789.4
(0.41%)
INR 789.4
(0.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.32 Billion INR | -33.33% |
| 2022 | 1.64 Billion INR | -20.19% |
| 2021 | 2.06 Billion INR | -4.58% |
| 2020 | 2.15 Billion INR | -4.43% |
| 2019 | 2.25 Billion INR | -8.96% |
| 2018 | 2.48 Billion INR | -7.18% |
| 2017 | 2.67 Billion INR | -10.3% |
| 2016 | 2.98 Billion INR | -25.15% |
| 2015 | 3.98 Billion INR | -22.78% |
| 2014 | 5.15 Billion INR | 9.93% |
| 2013 | 4.69 Billion INR | -11.76% |
| 2012 | 5.31 Billion INR | -0.21% |
| 2011 | 5.32 Billion INR | 11.99% |
| 2010 | 4.75 Billion INR | 27.61% |
| 2009 | 3.72 Billion INR | 7.42% |
| 2008 | 3.47 Billion INR | 12.73% |
| 2007 | 3.07 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 383.8 Million INR | 101.68% |
| 2024 Q2 | 379.5 Million INR | -16.18% |
| 2023 Q4 | 190.3 Million INR | -51.27% |
| 2023 FY | 1.09 Billion INR | -33.33% |
| 2023 Q2 | 340.4 Million INR | -10.09% |
| 2023 Q3 | 390.5 Million INR | 14.72% |
| 2023 Q1 | 378.6 Million INR | 116.22% |
| 2022 Q2 | 504.9 Million INR | -20.45% |
| 2022 Q3 | 330.2 Million INR | -34.6% |
| 2022 FY | 1.64 Billion INR | -20.19% |
| 2022 Q4 | 175.1 Million INR | -46.97% |
| 2022 Q1 | 634.7 Million INR | 90.72% |
| 2021 Q4 | 332.8 Million INR | -39.72% |
| 2021 FY | 2.06 Billion INR | -4.58% |
| 2021 Q1 | 581.9 Million INR | 20.93% |
| 2021 Q2 | 594.2 Million INR | 2.11% |
| 2021 Q3 | 552.1 Million INR | -7.09% |
| 2020 FY | 2.15 Billion INR | -4.43% |
| 2020 Q3 | 516.3 Million INR | -12.65% |
| 2020 Q1 | 571.2 Million INR | 44.39% |
| 2020 Q4 | 481.2 Million INR | -6.8% |
| 2020 Q2 | 591.1 Million INR | 3.48% |
| 2019 Q1 | 578.7 Million INR | 65.82% |
| 2019 Q4 | 395.6 Million INR | -43.65% |
| 2019 FY | 2.25 Billion INR | -8.96% |
| 2019 Q2 | 583.6 Million INR | 0.85% |
| 2019 Q3 | 702 Million INR | 20.29% |
| 2018 FY | 2.48 Billion INR | -7.18% |
| 2018 Q4 | 349 Million INR | -55.35% |
| 2018 Q3 | 781.6 Million INR | 37.58% |
| 2018 Q2 | 568.1 Million INR | -27.5% |
| 2018 Q1 | 783.6 Million INR | 14.83% |
| 2017 Q1 | 615.6 Million INR | -17.09% |
| 2017 FY | 2.67 Billion INR | -10.3% |
| 2017 Q3 | 923.3 Million INR | -4.06% |
| 2017 Q2 | 962.4 Million INR | 56.34% |
| 2017 Q4 | 682.4 Million INR | -26.09% |
| 2016 Q1 | 898.2 Million INR | -4.6% |
| 2016 Q2 | 924.9 Million INR | 2.97% |
| 2016 FY | 2.98 Billion INR | -25.15% |
| 2016 Q4 | 742.5 Million INR | -20.65% |
| 2016 Q3 | 935.7 Million INR | 1.17% |
| 2015 FY | 3.98 Billion INR | -22.78% |
| 2015 Q4 | 941.5 Million INR | -9.32% |
| 2015 Q3 | 1.03 Billion INR | -20.74% |
| 2015 Q2 | 1.31 Billion INR | 2.49% |
| 2015 Q1 | 1.27 Billion INR | -6.4% |
| 2014 FY | 5.15 Billion INR | 9.93% |
| 2014 Q1 | 1.2 Billion INR | 1.29% |
| 2014 Q2 | 1.36 Billion INR | 13.44% |
| 2014 Q3 | 1.27 Billion INR | -6.84% |
| 2014 Q4 | 1.36 Billion INR | 7.41% |
| 2013 Q4 | 1.18 Billion INR | 0.66% |
| 2013 FY | 4.69 Billion INR | -11.76% |
| 2013 Q3 | 1.17 Billion INR | 7.43% |
| 2013 Q2 | 1.09 Billion INR | -10.39% |
| 2013 Q1 | 1.22 Billion INR | -2.1% |
| 2012 Q4 | 1.25 Billion INR | -9.04% |
| 2012 FY | 5.31 Billion INR | -0.21% |
| 2012 Q1 | 1.33 Billion INR | 8.82% |
| 2012 Q2 | 1.35 Billion INR | 1.55% |
| 2012 Q3 | 1.37 Billion INR | 1.5% |
| 2011 FY | 5.32 Billion INR | 11.99% |
| 2011 Q2 | 1.41 Billion INR | 0.0% |
| 2011 Q3 | 1.39 Billion INR | -1.23% |
| 2011 Q4 | 1.22 Billion INR | -12.14% |
| 2010 FY | 4.75 Billion INR | 27.61% |
| 2009 FY | 3.72 Billion INR | 7.42% |
| 2008 FY | 3.47 Billion INR | 12.73% |
| 2007 FY | 3.07 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 95.045% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.142% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 89.328% |
| Granules India Limited | 16.79 Billion INR | 92.101% |
| Indoco Remedies Limited | 6.04 Billion INR | 78.036% |
| Achyut Healthcare Limited | 4.86 Million INR | -27196.852% |
| Ajanta Pharma Limited | 21.06 Billion INR | 93.701% |
| Alkem Laboratories Limited | 52.29 Billion INR | 97.463% |
| Alpa Laboratories Limited | 188.89 Million INR | -602.454% |
| Brooks Laboratories Limited | 65.62 Million INR | -1922.097% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 78.676% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 9.845% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 64.094% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.189% |
| Eris Lifesciences Limited | 10.42 Billion INR | 87.274% |
| FDC Limited | 8.33 Billion INR | 84.08% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.086% |
| Gufic Biosciences Limited | 4.16 Billion INR | 68.162% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 78.579% |
| Ipca Laboratories Limited | 29.8 Billion INR | 95.549% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -103.328% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -588.487% |
| Lasa Supergenerics Limited | 121.02 Million INR | -996.34% |
| Laurus Labs Limited | 24.62 Billion INR | 94.611% |
| Lupin Limited | 123.71 Billion INR | 98.927% |
| Mankind Pharma Limited | 44.52 Billion INR | 97.02% |
| Medicamen Biotech Limited | 495.49 Million INR | -167.793% |
| Medico Remedies Limited | 262.14 Million INR | -406.172% |
| Megasoft Limited | 342.07 Million INR | -287.902% |
| NATCO Pharma Limited | 25.73 Billion INR | 94.844% |
| Piramal Pharma Limited | 24.47 Billion INR | 94.578% |
| RPG Life Sciences Limited | 2.48 Billion INR | 46.561% |
| Sigachi Industries Limited | 2 Billion INR | 33.731% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.487% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 67.819% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -40.8% |
| Unichem Laboratories Limited | 4.86 Billion INR | 72.725% |
| Wanbury Limited | 1.73 Billion INR | 23.329% |
| Windlas Biotech Limited | 1.33 Billion INR | 0.889% |
| ZIM Laboratories Limited | 1.26 Billion INR | -4.737% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.94% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 320.267% |
| Divi's Laboratories Limited | 32.44 Billion INR | 95.91% |
| Hester Biosciences Limited | 1.27 Billion INR | -4.181% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 77.049% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 14.753% |
| Bal Pharma Limited | 770.19 Million INR | -72.281% |
| Strides Pharma Science Limited | 14.38 Billion INR | 90.778% |
| Venus Remedies Limited | 2.18 Billion INR | 39.205% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 77.245% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 55.354% |
| Shilpa Medicare Limited | 3.54 Billion INR | 62.589% |
| Aarti Drugs Limited | 8.31 Billion INR | 84.044% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 71.033% |
| Suven Life Sciences Limited | -200.79 Million INR | 760.817% |
| Ind-Swift Limited | 2.17 Billion INR | 38.924% |
| Valiant Laboratories Limited | -60.66 Million INR | 2287.294% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 94.155% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -54.076% |
| Themis Medicare Limited | 1.5 Billion INR | 11.77% |
| Hikal Limited | 3.14 Billion INR | 57.783% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 97.162% |
| Sequent Scientific Limited | 2.97 Billion INR | 55.454% |
| Wockhardt Limited | 16.24 Billion INR | 91.829% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 93.245% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -9001.01% |
| Neuland Laboratories Limited | 8.24 Billion INR | 83.912% |
| Morepen Laboratories Limited | 6.16 Billion INR | 78.464% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -113.852% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -88.586% |